Literature DB >> 25353058

Transient elastography compared to serum markers to predict liver fibrosis in a cohort of Chinese patients with chronic hepatitis B.

Jidong Jia1, Jinlin Hou, Huiguo Ding, Guofeng Chen, Qing Xie, Yuming Wang, Minde Zeng, Jingmin Zhao, Tailing Wang, Xiqi Hu, D Schuppan.   

Abstract

BACKGROUND AND AIM: Liver stiffness measurement (LSM) using transient elastography (FibroScan) is a useful tool to assess fibrosis in various chronic liver diseases. However, studies were mainly performed in Western countries and largely focused on chronic hepatitis C (CHC). We therefore carried out a multicenter study to validate the accuracy of LSM in the assessment of liver fibrosis in a large cohort of Chinese patients with chronic hepatitis B (CHB).
METHODS: We compared LSM results to histological staging and serum fibrosis markers (five direct markers, APRI and FIB-4) using Spearman correlation analysis and area under receiver operating characteristic (ROC) curves (AUROCs).
RESULTS: Four hundred sixty-nine patients were enrolled and eligible for statistical analysis. LSM in F0 to F4 was 5.5 ± 1.7, 5.8 ± 2.2, 7.6 ± 3.4, 14.5 ± 10.8, and 22.3 ± 13.6 kPa, respectively (correlation with fibrosis stage r = 0.522, P < 0.001). AUROC for LSM to correctly allocate patients to histological fibrosis stage ≥ F2, ≥ F3, and F4 was 0.82, 0.88, and 0.90, respectively. LSM outperformed serum fibrosis markers for detection of fibrosis F ≥ 2 and F4. Patients with ALT levels 1-5x and > 5x the upper limit of normal values had significantly higher stiffness values than stage-matched patients with normal alanine aminotransferase.
CONCLUSION: Transient elastography is a reliable noninvasive technique to predict significant liver fibrosis in Chinese patients with CHB, being superior to current biomarker panels. However, enhanced inflammatory activity can lead to elevated stiffness values unrelated to histological fibrosis stage.
© 2014 Journal of Gastroenterology and Hepatology Foundation and Wiley Publishing Asia Pty Ltd.

Entities:  

Keywords:  biomarker; fibrosis; inflammation; noninvasive; transient elastography

Mesh:

Substances:

Year:  2015        PMID: 25353058     DOI: 10.1111/jgh.12840

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  33 in total

1.  Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance.

Authors:  Norah A Terrault; Anna S F Lok; Brian J McMahon; Kyong-Mi Chang; Jessica P Hwang; Maureen M Jonas; Robert S Brown; Natalie H Bzowej; John B Wong
Journal:  Hepatology       Date:  2018-04       Impact factor: 17.425

2.  Changes of FibroScan, APRI, and FIB-4 in chronic hepatitis B patients with significant liver histological changes receiving 3-year entecavir therapy.

Authors:  Qiang Li; Liang Chen; Yu Zhou
Journal:  Clin Exp Med       Date:  2018-01-19       Impact factor: 3.984

3.  M2BPGi as a potential diagnostic tool of cirrhosis in Chinese patients with Hepatitis B virus infection.

Authors:  Bin Wei; Shu Feng; Enqiang Chen; Dongdong Li; Tingting Wang; Yu Gou; Tingting Yang; Dongmei Zhang; Chuanmin Tao; Hong Tang
Journal:  J Clin Lab Anal       Date:  2017-05-24       Impact factor: 2.352

4.  Association between non-alcoholic fatty liver disease and bone turnover markers in southwest China.

Authors:  Ying Liu; Ping Shuai; Yuping Liu; Dongyu Li
Journal:  J Bone Miner Metab       Date:  2022-05-31       Impact factor: 2.626

5.  Change of Cytokines in Chronic Hepatitis B Patients and HBeAg are Positively Correlated with HBV RNA, Based on Real-world Study.

Authors:  Qiqi Zhang; Hui Huang; Aijun Sun; Chunyan Liu; Zhidong Wang; Feifan Shi; Wei Duan; Xueying Sun; Qi Wang; Ping Sun; Chunwen Pu; Yong Zhang
Journal:  J Clin Transl Hepatol       Date:  2021-09-18

6.  The Gamma-Glutamyl-Transpeptidase to Platelet Ratio Does not Show Advantages than APRI and Fib-4 in Diagnosing Significant Fibrosis and Cirrhosis in Patients With Chronic Hepatitis B: A Retrospective Cohort Study in China.

Authors:  Qiang Li; Jie Song; Yuxian Huang; Xinyan Li; Qibin Zhuo; Weixia Li; Chong Chen; Chuan Lu; Xun Qi; Liang Chen
Journal:  Medicine (Baltimore)       Date:  2016-04       Impact factor: 1.889

7.  Evaluation of APRI and FIB-4 for noninvasive assessment of significant fibrosis and cirrhosis in HBeAg-negative CHB patients with ALT ≤ 2 ULN: A retrospective cohort study.

Authors:  Qiang Li; Xiaojing Ren; Chuan Lu; Weixia Li; Yuxian Huang; Liang Chen
Journal:  Medicine (Baltimore)       Date:  2017-03       Impact factor: 1.889

8.  Guideline of Prevention and Treatment for Chronic Hepatitis B (2015 Update).

Authors:  Jinlin Hou; Guiqiang Wang; Fusheng Wang; Jun Cheng; Hong Ren; Hui Zhuang; Jian Sun; Lanjuan Li; Jie Li; Qinghua Meng; Jingmin Zhao; Zhongping Duan; Jidong Jia; Hong Tang; Jifang Sheng; Jie Peng; Fengmin Lu; Qing Xie; Lai Wei
Journal:  J Clin Transl Hepatol       Date:  2017-11-12

Review 9.  Clinical Application of Vibration Controlled Transient Elastography in Patients with Chronic Hepatitis B.

Authors:  Xie-Er Liang; Yong-Peng Chen
Journal:  J Clin Transl Hepatol       Date:  2017-07-26

10.  Discrimination of Nonalcoholic Steatohepatitis Using Transient Elastography in Patients with Nonalcoholic Fatty Liver Disease.

Authors:  Hye Won Lee; Soo Young Park; Seung Up Kim; Jae Young Jang; Hana Park; Ja Kyung Kim; Chun Kyon Lee; Young Eun Chon; Kwang-Hyub Han
Journal:  PLoS One       Date:  2016-06-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.